Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Perspective Therapeutics Inc. (CATX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: CATX (3-star) is a WEAK-BUY. BUY since 11 days. Simulated Profits (-38.48%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $13.7
1 Year Target Price $13.7
| 10 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 193.44% | Avg. Invested days 43 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 222.05M USD | Price to earnings Ratio - | 1Y Target Price 13.7 |
Price to earnings Ratio - | 1Y Target Price 13.7 | ||
Volume (30-day avg) 14 | Beta 1.16 | 52 Weeks Range 1.60 - 12.90 | Updated Date 10/25/2025 |
52 Weeks Range 1.60 - 12.90 | Updated Date 10/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.37 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -8289.31% |
Management Effectiveness
Return on Assets (TTM) -15.32% | Return on Equity (TTM) -31.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 71168835 | Price to Sales(TTM) 179.79 |
Enterprise Value 71168835 | Price to Sales(TTM) 179.79 | ||
Enterprise Value to Revenue 68.73 | Enterprise Value to EBITDA -21.91 | Shares Outstanding 74262990 | Shares Floating 58977439 |
Shares Outstanding 74262990 | Shares Floating 58977439 | ||
Percent Insiders 18.82 | Percent Institutions 58.77 |
Upturn AI SWOT
Perspective Therapeutics Inc.
Company Overview
History and Background
Perspective Therapeutics, Inc., formerly known as Isotope Technologies Group, Inc., is a clinical-stage pharmaceutical company focused on developing radiopharmaceuticals for cancer treatment. Founded in 2017, the company aims to improve survival outcomes by leveraging its expertise in targeted alpha-particle therapy.
Core Business Areas
- Targeted Alpha Therapy: Develops targeted alpha-particle radiotherapies for various cancers, utilizing isotopes like Actinium-225.
- Imaging Agents: Develops imaging agents to identify and stage cancers, which assist in determining treatment suitability.
Leadership and Structure
The leadership team includes experienced executives in pharmaceuticals, oncology, and finance. The company's structure involves departments focused on research and development, clinical trials, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- 131I-MIP: A targeted therapy for neuroendocrine tumors (NETs). The therapy is currently in clinical trials. The company is aiming for a share of the NETs theranostics market, which is dominated by Novartis's Lutathera. Competitors include Advanced Accelerator Applications, a Novartis company.
- Actinium-225 (Ac225) based Therapies: Perspective is developing therapies using Ac225 to target PSMA (prostate-specific membrane antigen) in prostate cancer. This includes drug candidates and research partnerships. Competitors for this technology include several companies in the radiopharmaceutical space, such as Bayer, Telix Pharmaceuticals and Curium.
Market Dynamics
Industry Overview
The radiopharmaceutical market is experiencing rapid growth driven by advancements in targeted therapies and imaging technologies. Increasing cancer prevalence and a growing demand for personalized medicine are also fueling market expansion.
Positioning
Perspective Therapeutics is positioning itself as a leader in targeted alpha-particle therapy. Their competitive advantage lies in their ability to utilize Ac225 and develop novel targeting agents.
Total Addressable Market (TAM)
The global radiopharmaceuticals market is projected to reach USD 12.2 billion by 2028. Perspective is positioned to capture a significant share of this market, particularly in the theranostics segment for neuroendocrine and prostate cancers.
Upturn SWOT Analysis
Strengths
- Novel targeted alpha therapy platform
- Experienced leadership team
- Strong intellectual property portfolio
- Promising clinical trial results
Weaknesses
- Limited commercialized products
- Reliance on clinical trial success
- High research and development costs
- Limited financial resources compared to larger competitors
Opportunities
- Expansion into new cancer indications
- Strategic partnerships with pharmaceutical companies
- Acquisition of complementary technologies
- Increased adoption of radiopharmaceuticals in cancer treatment
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Unfavorable clinical trial outcomes
- Manufacturing and supply chain challenges
Competitors and Market Share
Key Competitors
- NVTS
- BAYRY
- TLX
Competitive Landscape
Perspective Therapeutics competes with established pharmaceutical companies with greater resources. Perspective is trying to become the first and primary competitor by having the best product and services in the market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is defined by expansion in research and development activities and advancement of clinical trials. Revenue growth is limited at this stage.
Future Projections: Future growth is projected to be substantial if clinical trials are successful, leading to regulatory approvals and commercial launch of products. Analyst estimates vary based on probability of success in trials.
Recent Initiatives: Recent initiatives include advancing clinical trials for 131I-MIP, developing Ac225 based therapies, and expanding manufacturing capabilities.
Summary
Perspective Therapeutics is a clinical-stage company focused on developing radiopharmaceuticals for cancer. They have a novel approach, but they are still early in the commercial cycle. Positive clinical trial data, strategic partnerships, and successful commercial launch are critical for their success. Financial constraints and competition will be major challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The radiopharmaceutical industry is rapidly changing, and all investment decisions should be made by considering all available information and the specific needs of the investor. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Perspective Therapeutics Inc.
Exchange NYSE MKT | Headquaters Seattle, WA, United States | ||
IPO Launch date 2005-11-10 | CEO & Director Mr. Johan M. Spoor | ||
Sector Healthcare | Industry Medical Devices | Full time employees 138 | |
Full time employees 138 | |||
Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha; and PSV4XX, a differentiated prostate-specific membrane antigen-targeted alpha therapy. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.